[Mezlocillin: tissue concentration and efficacy (author's transl)]. 1979

E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn

Studies on serum and tissue (cutis, muscle and liver) concentrations were carried out with mezlocillin (Baypen), a semi-synthetic new acyl ureidopenicillin, in 51 patients. Serum half life was 59 minutes. The highest concentrations were measured in the cutis, the lowest in the muscles. Concentrations in the liver were found to be relatively constant and persistent.--The efficacy and tolerance of mezlocillin were examined in 48 patients affected by 56 mostly severe infections, which were treated with a dose of 5 g twice or three times daily. The indications for antibiotic treatment were bronchopulmonary infections, peritonitis, soft tissue infections, biliary and urinary tract infections and postoperative febrile conditions of unknown origin. Clinical cure was achieved in 78.5% and an improvement of symptoms in 5.4% of infections. 76% of the causative microorganisms were eliminated. Mezlocillin was locally and systemically well tolerated.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005335 Fever of Unknown Origin Fever in which the etiology cannot be ascertained. Unknown Origin Fever,Unknown Origin Fevers
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
February 1982, La Nouvelle presse medicale,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
February 1982, La Nouvelle presse medicale,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
January 1980, Archives of oto-rhino-laryngology,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
January 1979, Arzneimittel-Forschung,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
January 1988, Chemotherapy,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
February 1982, La Nouvelle presse medicale,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
February 1982, La Nouvelle presse medicale,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
February 1982, La Nouvelle presse medicale,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
January 1980, Therapie,
E Helwing, and M Lux, and W Düben, and J Potel, and D Tettenborn
January 1978, Infection,
Copied contents to your clipboard!